Blog

Applications are open for the PREVENT Cancer Preclinical Drug Development Program – NCI Division of Cancer Prevention

Photo taken from NCI Division of Cancer Prevention/LinkedIn

Oct 10, 2024, 18:51

Applications are open for the PREVENT Cancer Preclinical Drug Development Program – NCI Division of Cancer Prevention

NCI Division of Cancer Prevention posted the following on LinkedIn:

“The National Cancer Institute (NCI) PREVENT Cancer Preclinical Drug Development Program (PREVENT) is accepting applications to support the preclinical development of innovative interventions and predictive biomarkers for cancer prevention and interception towards clinical applications in high-risk populations. Interested researchers from academia, industry, nonprofits, and government with innovative ideas in precision cancer prevention are encouraged to apply.

Deadline: Monday, November 4, 2024.

Find out more.”

Source: NCI Division of Cancer Prevention/LinkedIn

academia Application Deadline cancer Cancer Prevention clinical applications government high-risk populations industry National Cancer Institute NCI Division of Cancer Prevention nonprofits OncoDaily Oncology precision cancer prevention predictive biomarkers PREVENT Cancer Preclinical Drug Development Program researchers

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology